Shares of NxStage Medical, Inc. (NASDAQ:NXTM) have received a consensus rating of “Hold” from the six research firms that are presently covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation and five have assigned a hold recommendation to the company. The average 12 month target price among analysts that have covered the stock in the last year is $30.00.

Several equities research analysts recently commented on NXTM shares. BidaskClub raised shares of NxStage Medical from a “sell” rating to a “hold” rating in a research report on Tuesday, April 24th. ValuEngine cut shares of NxStage Medical from a “buy” rating to a “hold” rating in a research report on Thursday, June 28th. Finally, Zacks Investment Research cut shares of NxStage Medical from a “hold” rating to a “strong sell” rating in a research report on Tuesday, May 15th.

A number of institutional investors and hedge funds have recently bought and sold shares of NXTM. Renaissance Technologies LLC bought a new stake in NxStage Medical in the 4th quarter valued at $3,390,000. Guggenheim Capital LLC lifted its position in NxStage Medical by 35.5% in the 4th quarter. Guggenheim Capital LLC now owns 11,247 shares of the medical device company’s stock valued at $273,000 after acquiring an additional 2,949 shares in the last quarter. Millennium Management LLC bought a new stake in NxStage Medical in the 4th quarter valued at $896,000. NJ State Employees Deferred Compensation Plan lifted its position in NxStage Medical by 22.2% in the 1st quarter. NJ State Employees Deferred Compensation Plan now owns 44,000 shares of the medical device company’s stock valued at $1,094,000 after acquiring an additional 8,000 shares in the last quarter. Finally, SG Americas Securities LLC lifted its position in NxStage Medical by 154.6% in the 1st quarter. SG Americas Securities LLC now owns 26,576 shares of the medical device company’s stock valued at $661,000 after acquiring an additional 16,136 shares in the last quarter. 80.44% of the stock is currently owned by institutional investors and hedge funds.

NXTM opened at $28.15 on Wednesday. The firm has a market capitalization of $1.86 billion, a P/E ratio of -128.38 and a beta of 0.02. NxStage Medical has a 12 month low of $22.70 and a 12 month high of $29.34.

NxStage Medical Company Profile

NxStage Medical, Inc, a medical technology company, develops, manufactures, and markets products and services for patients suffering from chronic or acute kidney failure. Its primary product includes the System One, a portable hemodialysis system, which is used primarily for home hemodialysis and a range of dialysis therapies to deliver in the home setting.

Read More: Why Dividend Stocks May Be Right for You

Receive News & Ratings for NxStage Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NxStage Medical and related companies with MarketBeat.com's FREE daily email newsletter.